New indication for Celebrex

The licence for Celebrex (celecoxib) has been extended to include symptomatic relief in the treatment of ankylosing spondylitis. Celebrex was already licensed for symptomatic relief in the treatment of osteoarthritis and rheumatoid arthritis.

The recommended daily dose of Celebrex for patients with ankylosing spondylitis is 200mg taken once daily or in two divided doses. A maximum dose of 400mg daily may be required in some patients. Therapeutic benefit should be assessed after two weeks of use.

Further information: Pharmacia 01304 616161

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases